These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 37295865)
21. Concurrent use of omalizumab and dupilumab in a 47-year-old woman with chronic spontaneous urticaria and atopic dermatitis. Holm JG; Sørensen JA; Thomsen SF Int J Dermatol; 2022 May; 61(5):e173-e174. PubMed ID: 34813086 [No Abstract] [Full Text] [Related]
23. The Role of Adjuvant Therapy in the Management of Chronic Urticaria. Keumala Budianti W; Mahri S; Almira D Actas Dermosifiliogr; 2023 Jun; 114(6):T523-T530. PubMed ID: 37172893 [TBL] [Abstract][Full Text] [Related]
24. The Role of Adjuvant Therapy in the Management of Chronic Urticaria. Keumala Budianti W; Mahri S; Almira D Actas Dermosifiliogr; 2023 Jun; 114(6):523-530. PubMed ID: 36871821 [TBL] [Abstract][Full Text] [Related]
25. Comment on ''how does omalizumab affect the immunoinflammatory response in patients with chronic spontaneous urticaria?'': reply from author. Önder S; Ozturk M Cutan Ocul Toxicol; 2020 Mar; 39(1):73. PubMed ID: 31899976 [TBL] [Abstract][Full Text] [Related]
27. The Comparative Safety of Multiple Alternative Agents in Refractory Chronic Urticaria Patients. Seth S; Khan DA J Allergy Clin Immunol Pract; 2017; 5(1):165-170.e2. PubMed ID: 27746265 [TBL] [Abstract][Full Text] [Related]
28. Impact of Pharmacological Treatments for Chronic Spontaneous Urticaria with an Inadequate Response to H1-Antihistamines on Health-Related Quality of Life: A Systematic Review and Network Meta-Analysis. Nochaiwong S; Chuamanochan M; Ruengorn C; Awiphan R; Tovanabutra N; Chiewchanvit S; Hutton B; Thavorn K J Allergy Clin Immunol Pract; 2022 Jan; 10(1):297-308. PubMed ID: 34695599 [TBL] [Abstract][Full Text] [Related]
29. Efficacy of the colchicine add-on therapy in patients with autoimmune chronic urticaria. Nabavizadeh SH; Babaeian M; Esmaeilzadeh H; Mortazavifar N; Alyasin S Dermatol Ther; 2021 Nov; 34(6):e15119. PubMed ID: 34469631 [TBL] [Abstract][Full Text] [Related]
30. Age and fast initial response predict omalizumab retreatment in chronic urticaria. Meertens MAJ; Luijf T; van Lindonk EAM; Soegiharto R; Assil S; Alizadeh Aghdam M; Kentie PA; Knulst AC; van Doorn MBA; Röckmann H J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3556-3558.e1. PubMed ID: 37517795 [No Abstract] [Full Text] [Related]
31. Effects of omalizumab on basophils: Potential biomarkers in asthma and chronic spontaneous urticaria. Poddighe D; Vangelista L Cell Immunol; 2020 Dec; 358():104215. PubMed ID: 33137647 [TBL] [Abstract][Full Text] [Related]
32. Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria. Pedersen NH; Sørensen JA; Ghazanfar MN; Zhang DG; Vestergaard C; Thomsen SF Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511088 [TBL] [Abstract][Full Text] [Related]
33. [Practical update for the diagnosis and treatment of chronic urticaria]. La Forgia MP; Torre AC; Song A; Ritchie CA; Medina I; Cannavó A; Luna PC; Gattolin G; Gomez M Medicina (B Aires); 2023; 83(5):772-792. PubMed ID: 37870335 [TBL] [Abstract][Full Text] [Related]
34. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis. He ZH; Qiu SC; Huang ZW; Zhang GQ; An QQ; Qu F; Wang N Dermatol Ther; 2022 Dec; 35(12):e15928. PubMed ID: 36222320 [TBL] [Abstract][Full Text] [Related]
35. Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study. Abduelmula A; Georgakopoulos JR; Mufti A; Devani AR; Gooderham MJ; Hong CH; Jain V; Lansang P; Vender R; Prajapati VH; Yeung J J Cutan Med Surg; 2022; 26(3):319-320. PubMed ID: 34587789 [No Abstract] [Full Text] [Related]
36. Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria? Melé-Ninot G; Serra-Baldrich E; Spertino J; Guilarte M; Ribó González P; Lleonart-Bellfill R; Figueras-Nart I; Bonfill-Ortí M; Depreux N; Sala-Cunill A; Bielsa-Marsol I; Baliu-Piqué C; Sanmartín-Novell V; Garcia-Navarro X; Expósito-Serrano V; Garnica-Velandia D; Diaz-Sarrió MC; Gómez-Armayones S; Gich Saladich I; Giménez-Arnau A Eur J Dermatol; 2022 Sep; 32(5):629-631. PubMed ID: 36468733 [TBL] [Abstract][Full Text] [Related]
37. Consecutive injections of low-dose interleukin-2 improve symptoms and disease control in patients with chronic spontaneous urticaria. Wang J; He L; Yi W; Liang Q; Jiang L; Tan Y; Zhang G; Su Y; Xiao R; Lu Q; Long H Clin Immunol; 2023 Feb; 247():109247. PubMed ID: 36724835 [TBL] [Abstract][Full Text] [Related]
38. Current and Future Approaches in Management of Chronic Spontaneous Urticaria Using Anti-IgE Antibodies. Orzan OA; Popa LG; Mihai MM; Cojocaru A; Giurcăneanu C; Dorobanțu AM Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744079 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of omalizumab in chronic spontaneous urticaria associated with chronic inducible urticaria. Dortas Junior S; Azizi G; Valle S Ann Allergy Asthma Immunol; 2020 Oct; 125(4):486-487. PubMed ID: 32544531 [No Abstract] [Full Text] [Related]